ProCE Banner Activity

Novel PARP Inhibitor–Based Combinations Targeting Improved Patient Outcomes in Prostate Cancer

Text Module

Review expert insights on PARP inhibitor combination approaches including combinations with AR-directed therapy and immune checkpoint inhibitors.

Released: April 12, 2021

Expiration: April 11, 2022

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Learning Objectives

  • Describe the medical need and rationale for PARP inhibitor–based combinations in prostate cancer with or without DNA damage repair alterations
  • Plan therapeutic strategies to increase the depth and duration of response in men with prostate cancer
  • Evaluate the available clinical evidence on combination therapies including PARP inhibitors with androgen receptor–targeting agents or other therapies in metastatic CRPC
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Faculty Disclosure

Primary Author

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has received consulting fees from Advanced Accelerator Applications, Bayer, Dendreon, Roivant, and Pfizer; and has received funds for research support from Bayer, Clovis Oncology, and Sanofi-Genzyme.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.